||EPS - Basic
||Market Cap (m)
|Health Care Equipment & Services
Real-Time news about Shiloh (London Stock Exchange): 0 recent articles
|picnic: According to the Synergy results statement today they expect"..the award of 4 wave one contracts this summer"for NHS Sterilisation services.Hope springs eternal that SLH will actually get one.Might even be positive for the share price in expectation.|
|picnic: Well they have sold the Retail Division of Active Care for £210,000 which is more than likely a good move , will go towards paying back debt which is still
high.They should be getting a new Finance Director next month , hope he has
plenty of red ink for his first day in the office!
Too early to say whether this a good recovery play but I would not be suprised to see this as a turnaround point for the share price.
Still holding , considering a top up.|
|ben franklin: Their share price was falling on a daily basis and the only effective way to try and stop that is to put the results into the market early so that investors can judge what current trading is like.|
|ben franklin: I read through this discussion thread last evening - some very impressive, informative and interesting research and such a shame the thread's gone so quiet of late. Hopefully there's some new information below for anyone interested.
Mr Gartside seems a genuine person, but it is hard to be absolutely certain about the character and track record of the two new directors, Messrs Collyer and George. Nothing proven in the past but it is possible the share price will suffer until they prove themselves in Shiloh and overcome any lingering concerns .
In the last Shiloh report they are both listed as directors of Altrix Healthcare plc. Dieno George was appointed Chairman and Graham Collyer appointed Chief Executive of Altrix on 28 November 2001. Mr George says in his chairman's statement that they are driving Altrix to flotation.
On that basis it's a bit hard to see how Graham Collyer can be both Chief Executive designate of Shiloh and Chief Executive of Altrix. Something has to give, either Shiloh acquiring Altrix or Graham Collyer leaving Altrix.
Altrix's latest results (year to September 2001) show group net liabilities of £177,000 and pre tax losses (before exceptional costs) of £1.3 million on sales of £961,000.
Whilst Altrix may well have very good prospects (its sales had more than doubled in a year), a successful established business it certainly is not.
Hopefully Mr Gartside will structure any acquisition of Altrix very, very carefully. Uncertainty over the terms and timing of any such deal will not help the shares.
2. Current Trading and Broker Forecast
From the last annual report it's clear that Shiloh Healthcare (which last year accounted for around half Shiloh's total sales) made very little if any money. The previous year it made £0.7m operating profit on £17m sales, so sales went up £3m and profits dropped a lot. The uncertainty is whether or not this particular subsidiary can consistently make decent profits, or is it just tying up capital that would be better invested elsewhere?
The group's broker, WH Ireland, cut its forecast (on 31/5/02) for the year to March 2003 to £1.6m profit - earnings per share of 16.4p and dividends per share of 5.7p. That revised EPS figure was down very substantially on the 23p EPS WH Ireland was previously forecasting for the same period and now represents only limited growth over the year to March 2002.
EPS for the year to 31/3/04 is forecast by WH Ireland at 20.6p (DPS 6.25p).
My guess is these shares could drift quite a bit lower until the uncertainties above are successfully resolved (which hopefully they will be).
Anyone else got a view on them?
I tried to tweek the spread sheet I use to workout the EPS growth re the earlier post to get the 140%. I've just done the same calculation long hand
and have confirmed that the difference between the current rolling EPS (14.31) and the march EPS (29.11) is actually 103%. This would give a share price of 575 on the current P/E. However, the P/E for this stock is 15% above the sector average, and therefore a fair price against the current sector P/E is 490. This makes for a 73% increase in share price. Still not bad.
Sorry about the earlier mis calculation, hopefully no one will have taken it too literally and re mortgaged their house on the information.
PS My head hurts now after all that maths, so I'll think I'll have a lie down.|
|alfwilson: Can anyone help?
It is a while since I took a look at SLH and back then eps forecast was 18.2p (02) and 27.1p (03) and share price was 230p. Now the share price is 291p and eps forecasts are 14.6p (02) and 23.0p (03). Although long term (12 months) they look like a good bet ... I have target price of about 400p ... IMHO they currently look just a touch ahead of the game? Have I missed something?|
|mike012321: Thanks very much for link,Salar.
The story struck me as very peculiar.I had felt that the increase in share price could perhaps be attributed to the recent,very positive and well-publicised statements from the Govt re its commitment to increased funding for NHS,including increases in taxation.
Perhaps also the company is becoming better known?|
|doubleorquits: Don't know about this - couldn't find it when I looked - but this is a case of too many rumours and not enough fact. Perhaps company should issue a statement, after all shares have fallen 10%.
Unless estimates are wide of mark share price of 316p is justified on a forward PE of 12.
Statement of fact required, please directors.|
|greatbear: This share was well over sold. No way that the tonsillectomy issue is worth 20% of their profits!! Excellent buying opportunity. Topped up at a bargin price of 227 on Xmas eve. I expect to make 10-20% on this purchase well within a month, and potentially DOUBLE their share price within 12 months.
|jrb: David Cicurel had 11% (approximately 715k shares) at the beginning of January. I think it's fairly safe to assume that they have now all gone. Despite the liquidation of such a large holding, the share price has risen by 67% in 11 months during a severe bear market, so it looks as if the shares have gone into firm hands.
With that huge overhang out of the way, I think we may hope that the price of Shiloh will at last start to reflect its value. Current forecasts are still for earnings per share of 18.2p (+28%) this year to 31 March, and 27.10p (+49%) next year. If the forecasts look like being met, I don't think it would be unreasonable to expect a historic PE of 20 by March 2002, giving a price of 370p.
A historic PE of 20 by March 2003 would give us a price of 550p, and... well, even a hardened old investor like myself may dream!|
Shiloh share price data is direct from the London Stock Exchange